Anna C. Renner

Advancing Next-Generation Psychedelic Therapeutics through Selective 5-HT2A Activation, Precision Aerosol Delivery, and Optimized 5-MeO-DMT Treatment Paradigms

ACS Medicinal Chemistry Letters July 10, 2026 Anna C. Renner, Robert B. Kargbo

The psychedelic therapeutics field is moving beyond classical hallucinogens to integrated treatment platforms that combine optimized pharmacology, drug delivery, and clinical implementation. Recent patent applications describe selective 5-HT2A receptor activators, precision aerosol delivery technologies for psychedelic compounds, and structured 5-MeO-DMT treatment regimens for depression. These innovations represent a convergence toward scalable, safer, and clinically practical neuropsychiatric therapies that may reshape the future of serotonergic medicine.

DOI: 10.1021/acsmedchemlett.6c00364 Aerosol Precision medicine Computer science Nanotechnology

Advances in Psychedelic Therapeutics: Multimodal Iboga Analogs, EEG-Guided Psilocybin Dosing, and Optimized Harmine–DMT Formulations

ACS Medicinal Chemistry Letters December 16, 2025 Anna C. Renner, Robert B. Kargbo

Recent inventions create a framework for safer, more reliable psychedelic medicines. Simplified iboga analogs offer tunable polypharmacology, real-time EEG biomarkers personalize psilocybin dosing, and standardized harmine-DMT ratios achieve high bioavailability. These innovations improve mechanistic precision, receptor selectivity, and pharmacokinetic control.

DOI: 10.1021/acsmedchemlett.5c00714 Full text Psilocybin Electroencephalography Hallucinogen Investigational drugs +4

Molecular Diagnostics, Circuit-Calming Modulators, and Controlled Neuroplastogens: Emerging Strategies in Precision Neuropsychiatric Therapeutics

ACS Medicinal Chemistry Letters December 16, 2025 Anna C. Renner, Robert B. Kargbo

Three new approaches in neuropsychiatric therapeutics are converging: a blood test measuring FOXG1 gene expression for objective PTSD detection; benzocyclobutenyl-methylamine compounds that reduce excessive neuronal firing; and a sublingual 5-MeO-DMT formulation that promotes neuroplasticity without hallucinations. These advances link molecular diagnostics, targeted neural circuit modulation, and scalable treatments for affective disorders.

DOI: 10.1021/acsmedchemlett.5c00716 Full text Neuroscience Computer science Scalability Computational biology +2

Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy

ACS Medicinal Chemistry Letters October 10, 2025 Anna C. Renner, Robert B. Kargbo

A new crystalline cocrystal combining psilocin and psilocybin increases drug exposure, boosts markers of neuroplasticity, and alters functional brain activity. Adding atypical antipsychotics to the treatment changes serotonin signaling, reducing safety risks linked to the 5-HT2B receptor, which is associated with heart valve problems. These chemical advances improve how the therapy works, its selectivity for desired effects, and the ability to measure its impact in lab models. Together, they offer a chemistry-based way to develop scalable psychedelic treatments that are safer for the heart and produce lasting neuroplastic changes, as shown in organoid and animal studies.

DOI: 10.1021/acsmedchemlett.5c00595